Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 11 | 2024 | 296 | 3.810 |
Why?
|
| Onychomycosis | 6 | 2016 | 8 | 2.900 |
Why?
|
| Skin Neoplasms | 15 | 2025 | 880 | 2.890 |
Why?
|
| Foot Dermatoses | 4 | 2016 | 7 | 1.960 |
Why?
|
| Public Health | 3 | 2024 | 270 | 1.830 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2024 | 98 | 1.630 |
Why?
|
| Melanoma | 7 | 2025 | 898 | 1.530 |
Why?
|
| Keratosis, Actinic | 4 | 2020 | 14 | 1.180 |
Why?
|
| Skin Diseases | 2 | 2023 | 137 | 1.020 |
Why?
|
| Tinea | 2 | 2016 | 6 | 0.970 |
Why?
|
| Dermatology | 2 | 2022 | 30 | 0.970 |
Why?
|
| Candidiasis, Oral | 1 | 2024 | 2 | 0.900 |
Why?
|
| Vulvar Neoplasms | 1 | 2025 | 21 | 0.900 |
Why?
|
| Mycobacterium avium Complex | 1 | 2024 | 20 | 0.900 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2024 | 24 | 0.890 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2024 | 131 | 0.850 |
Why?
|
| Felty Syndrome | 1 | 2023 | 2 | 0.850 |
Why?
|
| Hand Dermatoses | 1 | 2023 | 10 | 0.840 |
Why?
|
| Sweet Syndrome | 1 | 2023 | 10 | 0.840 |
Why?
|
| Dermatitis | 1 | 2023 | 26 | 0.830 |
Why?
|
| Crows | 1 | 2022 | 1 | 0.770 |
Why?
|
| Fungemia | 1 | 2022 | 21 | 0.760 |
Why?
|
| Skin Lightening Preparations | 1 | 2022 | 1 | 0.750 |
Why?
|
| Neutropenia | 1 | 2023 | 198 | 0.750 |
Why?
|
| Administration, Cutaneous | 8 | 2020 | 65 | 0.740 |
Why?
|
| Invasive Fungal Infections | 1 | 2022 | 19 | 0.740 |
Why?
|
| Impetigo | 2 | 2018 | 5 | 0.730 |
Why?
|
| Quinolones | 2 | 2018 | 56 | 0.710 |
Why?
|
| Muscle Neoplasms | 1 | 2021 | 22 | 0.700 |
Why?
|
| Lipoma | 1 | 2021 | 24 | 0.700 |
Why?
|
| Aminopyridines | 2 | 2018 | 61 | 0.690 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 398 | 0.690 |
Why?
|
| Doxycycline | 2 | 2020 | 119 | 0.680 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 140 | 0.670 |
Why?
|
| Catheterization, Peripheral | 1 | 2022 | 128 | 0.660 |
Why?
|
| Travel-Related Illness | 1 | 2020 | 7 | 0.650 |
Why?
|
| Spotted Fever Group Rickettsiosis | 1 | 2020 | 5 | 0.650 |
Why?
|
| Rickettsia Infections | 1 | 2020 | 7 | 0.650 |
Why?
|
| Rickettsia | 1 | 2020 | 16 | 0.650 |
Why?
|
| Masks | 1 | 2020 | 37 | 0.640 |
Why?
|
| Diterpenes | 1 | 2020 | 30 | 0.630 |
Why?
|
| Dermatomycoses | 4 | 2024 | 16 | 0.630 |
Why?
|
| Dermatologic Agents | 1 | 2020 | 29 | 0.620 |
Why?
|
| Refusal to Treat | 1 | 2019 | 9 | 0.620 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 128 | 0.620 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 75 | 0.620 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2019 | 1 | 0.620 |
Why?
|
| Anti-Bacterial Agents | 5 | 2020 | 2519 | 0.620 |
Why?
|
| Erythema | 1 | 2019 | 27 | 0.610 |
Why?
|
| Humans | 51 | 2025 | 127268 | 0.600 |
Why?
|
| Nail Biting | 1 | 2019 | 4 | 0.600 |
Why?
|
| Treatment Refusal | 1 | 2019 | 77 | 0.590 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 53 | 0.590 |
Why?
|
| Trichotillomania | 1 | 2019 | 32 | 0.590 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 77 | 0.580 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 1110 | 0.580 |
Why?
|
| Standard of Care | 1 | 2019 | 133 | 0.580 |
Why?
|
| Triazoles | 5 | 2016 | 130 | 0.560 |
Why?
|
| Acetylcysteine | 1 | 2019 | 79 | 0.560 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 77 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1274 | 0.560 |
Why?
|
| Cheek | 1 | 2017 | 24 | 0.520 |
Why?
|
| Facial Neoplasms | 1 | 2017 | 21 | 0.510 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 1867 | 0.510 |
Why?
|
| Rosacea | 2 | 2024 | 13 | 0.510 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 48 | 0.510 |
Why?
|
| Informed Consent | 1 | 2019 | 337 | 0.500 |
Why?
|
| Boron Compounds | 4 | 2016 | 33 | 0.480 |
Why?
|
| Streptococcal Infections | 1 | 2018 | 247 | 0.470 |
Why?
|
| Aminoquinolines | 3 | 2010 | 35 | 0.470 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2016 | 41 | 0.470 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 362 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.450 |
Why?
|
| Biopsy | 3 | 2019 | 1237 | 0.440 |
Why?
|
| United States | 9 | 2025 | 11379 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 744 | 0.410 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 565 | 0.400 |
Why?
|
| Pandemics | 1 | 2020 | 1139 | 0.390 |
Why?
|
| Consensus | 2 | 2024 | 560 | 0.350 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 591 | 0.350 |
Why?
|
| Neglected Diseases | 2 | 2024 | 151 | 0.350 |
Why?
|
| Pyridones | 3 | 2016 | 137 | 0.340 |
Why?
|
| Skin Diseases, Parasitic | 2 | 2010 | 5 | 0.330 |
Why?
|
| Psoriasis | 2 | 2024 | 52 | 0.330 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2019 | 806 | 0.330 |
Why?
|
| Skin Diseases, Infectious | 1 | 2010 | 24 | 0.330 |
Why?
|
| Middle Aged | 13 | 2025 | 27807 | 0.320 |
Why?
|
| Skin Diseases, Bacterial | 2 | 2010 | 22 | 0.320 |
Why?
|
| Hot Temperature | 1 | 2010 | 138 | 0.310 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2009 | 10 | 0.310 |
Why?
|
| Prevalence | 3 | 2025 | 2613 | 0.300 |
Why?
|
| Azithromycin | 1 | 2008 | 43 | 0.280 |
Why?
|
| Treatment Outcome | 10 | 2024 | 12570 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 3264 | 0.280 |
Why?
|
| Dysplastic Nevus Syndrome | 2 | 2017 | 21 | 0.270 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 6694 | 0.270 |
Why?
|
| Aged | 10 | 2025 | 20427 | 0.260 |
Why?
|
| Silicone Gels | 1 | 2006 | 4 | 0.260 |
Why?
|
| Male | 17 | 2023 | 62778 | 0.260 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2006 | 7 | 0.260 |
Why?
|
| Cosmetic Techniques | 1 | 2006 | 11 | 0.250 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 73 | 0.250 |
Why?
|
| Entamoebiasis | 1 | 2006 | 3 | 0.250 |
Why?
|
| Entamoeba histolytica | 1 | 2006 | 14 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 886 | 0.250 |
Why?
|
| Delphi Technique | 2 | 2024 | 240 | 0.250 |
Why?
|
| Naphthalenes | 2 | 2016 | 38 | 0.240 |
Why?
|
| Skin | 3 | 2021 | 517 | 0.240 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1759 | 0.230 |
Why?
|
| Female | 14 | 2025 | 68592 | 0.230 |
Why?
|
| Administration, Topical | 4 | 2015 | 131 | 0.230 |
Why?
|
| Acupuncture Therapy | 1 | 2024 | 12 | 0.230 |
Why?
|
| Dielectric Spectroscopy | 1 | 2024 | 5 | 0.220 |
Why?
|
| Condylomata Acuminata | 2 | 2018 | 15 | 0.220 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2015 | 68 | 0.220 |
Why?
|
| Pruritus | 1 | 2024 | 48 | 0.220 |
Why?
|
| Algorithms | 2 | 2024 | 1635 | 0.220 |
Why?
|
| Complementary Therapies | 1 | 2024 | 40 | 0.220 |
Why?
|
| Filgrastim | 1 | 2023 | 12 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 680 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 637 | 0.210 |
Why?
|
| Blister | 1 | 2023 | 20 | 0.210 |
Why?
|
| Adult | 11 | 2025 | 30530 | 0.210 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 773 | 0.200 |
Why?
|
| Mohs Surgery | 2 | 2024 | 37 | 0.200 |
Why?
|
| Incidence | 3 | 2025 | 3260 | 0.200 |
Why?
|
| Double-Blind Method | 5 | 2018 | 1596 | 0.190 |
Why?
|
| Philippines | 1 | 2022 | 23 | 0.190 |
Why?
|
| Skin Pigmentation | 1 | 2022 | 27 | 0.190 |
Why?
|
| Recurrence | 2 | 2016 | 1422 | 0.190 |
Why?
|
| Drug Resistance, Fungal | 1 | 2022 | 28 | 0.190 |
Why?
|
| Molluscum Contagiosum | 1 | 2021 | 11 | 0.180 |
Why?
|
| Asia | 1 | 2022 | 123 | 0.180 |
Why?
|
| Candida | 1 | 2022 | 79 | 0.180 |
Why?
|
| Scapula | 1 | 2021 | 14 | 0.180 |
Why?
|
| India | 1 | 2022 | 228 | 0.180 |
Why?
|
| Young Adult | 5 | 2025 | 9694 | 0.170 |
Why?
|
| Dermatitis, Atopic | 1 | 2021 | 54 | 0.170 |
Why?
|
| Zimbabwe | 1 | 2020 | 7 | 0.160 |
Why?
|
| Skin Ulcer | 1 | 2020 | 31 | 0.160 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 66 | 0.160 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 733 | 0.160 |
Why?
|
| Dermatologists | 1 | 2019 | 5 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2020 | 122 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2019 | 26 | 0.150 |
Why?
|
| Back | 1 | 2019 | 12 | 0.150 |
Why?
|
| Surgeons | 1 | 2024 | 283 | 0.150 |
Why?
|
| Human papillomavirus 11 | 1 | 2018 | 2 | 0.150 |
Why?
|
| Human papillomavirus 6 | 1 | 2018 | 3 | 0.150 |
Why?
|
| Occupational Exposure | 1 | 2020 | 132 | 0.150 |
Why?
|
| Skin Cream | 1 | 2018 | 8 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2019 | 107 | 0.140 |
Why?
|
| Neck | 1 | 2019 | 141 | 0.140 |
Why?
|
| Streptococcus pyogenes | 1 | 2018 | 80 | 0.140 |
Why?
|
| Hydrogels | 1 | 2018 | 94 | 0.140 |
Why?
|
| Nevus, Pigmented | 1 | 2017 | 30 | 0.130 |
Why?
|
| Nevus | 1 | 2016 | 34 | 0.130 |
Why?
|
| Tinea Pedis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Europe | 2 | 2018 | 361 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 630 | 0.120 |
Why?
|
| Itraconazole | 1 | 2016 | 23 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3681 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 73 | 0.120 |
Why?
|
| Fluconazole | 1 | 2016 | 48 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2019 | 561 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 382 | 0.120 |
Why?
|
| Pharmaceutical Solutions | 1 | 2015 | 10 | 0.110 |
Why?
|
| Age Distribution | 1 | 2016 | 423 | 0.110 |
Why?
|
| Imidazoles | 1 | 2016 | 218 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2016 | 194 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2016 | 685 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2025 | 17051 | 0.100 |
Why?
|
| Sunscreening Agents | 1 | 2013 | 4 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2018 | 776 | 0.100 |
Why?
|
| Sunlight | 1 | 2013 | 27 | 0.100 |
Why?
|
| Margins of Excision | 3 | 2017 | 56 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2016 | 464 | 0.100 |
Why?
|
| Child | 6 | 2021 | 25274 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 456 | 0.100 |
Why?
|
| Australia | 1 | 2013 | 172 | 0.090 |
Why?
|
| Infant | 3 | 2018 | 12802 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 429 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 192 | 0.090 |
Why?
|
| Patient Selection | 1 | 2016 | 711 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 216 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2018 | 14443 | 0.090 |
Why?
|
| Research Design | 1 | 2015 | 694 | 0.090 |
Why?
|
| Porokeratosis | 1 | 2010 | 2 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2020 | 3589 | 0.080 |
Why?
|
| Comorbidity | 1 | 2016 | 1562 | 0.080 |
Why?
|
| Antimetabolites | 1 | 2010 | 28 | 0.080 |
Why?
|
| Skin Diseases, Viral | 1 | 2010 | 4 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 637 | 0.080 |
Why?
|
| Cryotherapy | 1 | 2010 | 13 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2010 | 132 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 900 | 0.080 |
Why?
|
| Adolescent | 4 | 2018 | 20141 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1239 | 0.080 |
Why?
|
| Risk Factors | 2 | 2016 | 10603 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2010 | 53 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3716 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2010 | 182 | 0.080 |
Why?
|
| Minocycline | 1 | 2008 | 42 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2010 | 380 | 0.070 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Ketoconazole | 1 | 2007 | 10 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 278 | 0.070 |
Why?
|
| Survival Rate | 1 | 2012 | 2105 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 1205 | 0.060 |
Why?
|
| Mass Screening | 1 | 2013 | 803 | 0.060 |
Why?
|
| Etanercept | 1 | 2006 | 44 | 0.060 |
Why?
|
| Transsexualism | 1 | 2006 | 14 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 129 | 0.060 |
Why?
|
| Thigh | 1 | 2006 | 50 | 0.060 |
Why?
|
| Anal Canal | 1 | 2006 | 79 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1197 | 0.060 |
Why?
|
| Animals | 2 | 2022 | 33187 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3325 | 0.060 |
Why?
|
| Capsaicin | 1 | 2024 | 19 | 0.060 |
Why?
|
| Penicillins | 1 | 2005 | 154 | 0.060 |
Why?
|
| Cephalosporins | 1 | 2005 | 137 | 0.060 |
Why?
|
| Chromoblastomycosis | 1 | 2024 | 1 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 386 | 0.050 |
Why?
|
| Drug Hypersensitivity | 1 | 2005 | 97 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 307 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 566 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 2995 | 0.050 |
Why?
|
| Tropical Medicine | 1 | 2024 | 103 | 0.050 |
Why?
|
| Cantharidin | 1 | 2021 | 1 | 0.050 |
Why?
|
| Curettage | 1 | 2021 | 6 | 0.050 |
Why?
|
| Prognosis | 2 | 2024 | 4791 | 0.050 |
Why?
|
| Global Health | 1 | 2006 | 609 | 0.040 |
Why?
|
| Dosage Forms | 2 | 2010 | 9 | 0.040 |
Why?
|
| Russia | 1 | 2018 | 38 | 0.040 |
Why?
|
| South Africa | 1 | 2018 | 99 | 0.040 |
Why?
|
| Dermoscopy | 1 | 2017 | 2 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 1760 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 131 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2018 | 467 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1596 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 303 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 2029 | 0.030 |
Why?
|
| Transcriptome | 1 | 2017 | 1053 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 299 | 0.020 |
Why?
|
| Leg | 1 | 2010 | 126 | 0.020 |
Why?
|
| Scalp | 1 | 2010 | 57 | 0.020 |
Why?
|
| Face | 1 | 2010 | 193 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5142 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 6160 | 0.010 |
Why?
|